Tempest Therapeutics, Inc. (TPST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 250K 500K 750K Q4 '14: 0 Q1 '15: 15K Q2 '15: 45K Q3 '15: 120K Q4 '15: 277K Q1 '16: 408K Q2 '16: 567K Q3 '16: 689K Q4 '16: 653K Q1 '17: 570K Q2 '17: 465K Q3 '17: 324K Q4 '17: 294K Q1 '18: 298K Q2 '18: 295K Q3 '18: 294K Q1 '15 Q3 '15 Q1 '16 Q3 '16 Q1 '17 Q3 '17 Q1 '18 Q3 '18

Gross Profit TTM

-6M -4M -2M 0 2M 4M 6M Q4 '14: 0 Q1 '15: -20K Q2 '15: -106K Q3 '15: -971K Q4 '15: -2M Q1 '16: -3M Q2 '16: -3.9M Q3 '16: -4.4M Q4 '16: -4.7M Q1 '17: -3.9M Q2 '17: -3.1M Q3 '17: -1.7M Q4 '17: -496K Q1 '18: -335K Q2 '18: -118K Q3 '18: -134K Q1 '15 Q3 '15 Q1 '16 Q3 '16 Q1 '17 Q3 '17 Q1 '18 Q3 '18

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: -53.9M Q4 '21: -27M Q1 '22: -30M Q2 '22: -32M Q3 '22: -33M Q4 '22: -34.6M Q1 '23: -34.1M Q2 '23: -32.8M Q3 '23: -30.6M Q4 '23: -29.2M Q1 '24: -29.6M Q2 '24: -31.7M Q3 '24: -35.6M Q4 '24: -42M Q1 '25: -45M Q2 '25: -43.4M Q3 '25: -36.4M Q4 '25: -26.6M Q1 '26: -43.4M Q2 '26: -40.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: -24.8M Q4 '21: -48.8M Q1 '22: -52M Q2 '22: -54.1M Q3 '22: -54.9M Q4 '22: -35.7M Q1 '23: -34.9M Q2 '23: -33.3M Q3 '23: -31.1M Q4 '23: -29.5M Q1 '24: -29.8M Q2 '24: -31.7M Q3 '24: -35.5M Q4 '24: -41.8M Q1 '25: -44.8M Q2 '25: -43.1M Q3 '25: -36.1M Q4 '25: -26.3M Q1 '26: -43.1M Q2 '26: -40.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 2M 4M 6M Q4 '14: 0 Q1 '15: 35K Q2 '15: 151K Q3 '15: 1.1M Q4 '15: 2.2M Q1 '16: 3.4M Q2 '16: 4.5M Q3 '16: 5.1M Q4 '16: 5.4M Q1 '17: 4.5M Q2 '17: 3.5M Q3 '17: 2M Q4 '17: 790K Q1 '18: 633K Q2 '18: 413K Q3 '18: 428K Q1 '15 Q3 '15 Q1 '16 Q3 '16 Q1 '17 Q3 '17 Q1 '18 Q3 '18

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -22.2M Q4 '21: -26M Q1 '22: -26.8M Q2 '22: -35.3M Q3 '22: -32.6M Q4 '22: -31.1M Q1 '23: -32.3M Q2 '23: -30.2M Q3 '23: -27.7M Q4 '23: -27.4M Q1 '24: -26.2M Q2 '24: -25.4M Q3 '24: -29.1M Q4 '24: -33M Q1 '25: -33.9M Q2 '25: -36.8M Q3 '25: -33.4M Q4 '25: -26.8M Q1 '26: -26.4M Q2 '26: -20.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -22.4M Q4 '21: -26.1M Q1 '22: -26.9M Q2 '22: -35.4M Q3 '22: -32.8M Q4 '22: -31.6M Q1 '23: -32.9M Q2 '23: -30.9M Q3 '23: -28.2M Q4 '23: -27.5M Q1 '24: -26.5M Q2 '24: -25.8M Q3 '24: -29.5M Q4 '24: -33.5M Q1 '25: -34.1M Q2 '25: -36.8M Q3 '25: -33.4M Q4 '25: -26.8M Q1 '26: -26.4M Q2 '26: -20.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 6M 12M 18M Q3 '20: 521.4K Q1 '21: 507.4K Q2 '21: 925.4K Q3 '21: 6.7M Q1 '22: 7.2M Q2 '22: 11.6M Q3 '22: 13.6M Q1 '23: 13.8M Q2 '23: 14.1M Q3 '23: 14.1M Q1 '24: 1.7M Q2 '24: 1.7M Q3 '24: 2M Q1 '25: 3.4M Q2 '25: 3.8M Q3 '25: 4.4M Q1 '26: 10.9M Q2 '26: 15.2M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q3 '21: -37.13 Q4 '21: -7.47 Q1 '22: 1.90 Q2 '22: 8.74 Q3 '22: 9.29 Q4 '22: -3.26 Q1 '23: -2.63 Q2 '23: -2.38 Q3 '23: -2.20 Q4 '23: -1.91 Q1 '24: -5.98 Q2 '24: -10.96 Q3 '24: -15.80 Q4 '24: -19.48 Q1 '25: -18.02 Q2 '25: -14.57 Q3 '25: -10.04 Q4 '25: -6.64 Q1 '26: -6.01 Q2 '26: -4.28 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.